Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike.
COVID-19
IgG
IgM
RBD
SARS-CoV-2
Spike glycoproteins
coronavirus
cross-reactivity, IgA
neutralization
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
20 10 2020
20 10 2020
Historique:
received:
12
06
2020
revised:
20
08
2020
accepted:
21
09
2020
pubmed:
6
10
2020
medline:
6
10
2020
entrez:
5
10
2020
Statut:
ppublish
Résumé
SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.
Identifiants
pubmed: 33015650
doi: 10.1016/j.xcrm.2020.100126
pii: S2666-3791(20)30168-3
pmc: PMC7524645
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Pagination
100126Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI122953
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Mol Biol. 2020 May 1;432(10):3309-3325
pubmed: 32320687
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93
pubmed: 15897467
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Nat Commun. 2020 May 27;11(1):2688
pubmed: 32461612
J Infect Dis. 2020 Jun 29;222(2):183-188
pubmed: 32358956
J Infect. 2020 Sep;81(3):e31-e32
pubmed: 32622905
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nat Microbiol. 2019 May;4(5):734-747
pubmed: 30886356
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Sci Immunol. 2020 May 13;5(47):
pubmed: 32404436
J Virol. 2009 Aug;83(15):7411-21
pubmed: 19439480
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
EMBO J. 1997 Feb 17;16(4):695-705
pubmed: 9049299
Nat Rev Immunol. 2010 Jul;10(7):514-26
pubmed: 20577268
J Virol. 2013 Mar;87(6):3097-107
pubmed: 23283955
Blood. 2020 Oct 01;:
pubmed: 33001206
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
PLoS One. 2013 Aug 30;8(8):e72942
pubmed: 24023659
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Science. 2020 Jul 17;369(6501):330-333
pubmed: 32366695
Cell Host Microbe. 2013 Oct 16;14(4):398-410
pubmed: 24055605
Curr Biol. 2020 Jun 8;30(11):2196-2203.e3
pubmed: 32416074
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Nat Immunol. 2018 Nov;19(11):1179-1188
pubmed: 30333615